Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - GU

Comparative whole-body multi-parametric [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT: a randomised and prospective intra-individual comparison of tracer dynamics

Ian Alberts, Hasan Sari, Clemens Mingels, Axel Rominger and Ali Afshar-Oromieh
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 242480;
Ian Alberts
1Provincial Health Services Authority (PHSA)/BC CANCER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hasan Sari
2Siemens Healthineers International AG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens Mingels
3University of California Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Axel Rominger
4Inselspital, Bern
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Afshar-Oromieh
5Department of Nuclear Medicine, University Hospital of Bern
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

242480

Introduction: Hitherto no randomised prospective trial data has been published for [18F]PSMA-1007. This protocol planned sub-study compares intra-individual [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 for healthy organs and target lesions to see if parametric analysis might reveal insights into in vivo radiopharmaceutical behaviour and in the characterisation of malignant tissues.

Methods: 10 patients with biochemically recurrent prostate cancer underwent both [68Ga]Ga-PSMA-11 (PSMA-11) or [18F]PSMA-1007 (PSMA-1007) PET/CT in randomised order as part of planned and approved sub-analysis of a prospective comparative imaging trial (NCT05079828) which shall recruit N=100 patients. Trial entry and exclusion criteria as well as endpoints are as previously published. Dynamic scans were acquired from 0 to 60 minutes using a long-axial field-of-view PET/CT with static imaging performed at 2h p.i. Healthy tissue and lesion segmentation was performed by a board certified nuclear medicine physician using 40% iso-contour where appropriate. Following model selection, data were fitted using a reversible two-tissue compartment (2TC) model. Non-specific activity at ganglia and foci of unspecific bone uptake (UBU) were also included. Values were compared using paired t-tests.

Alberts I, Bütikofer L, Rominger A, Afshar-Oromieh A (2022) A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT—Protocol design and rationale. PLoS ONE 17(7): e0270269. https://doi.org/10.1371/journal.pone.0270269

Results: Preliminary analysis of the target lesions showed no statistically significant differences or appreciable trends in tracer delivery (K1) for any tissue type or organ or between tracers. Faster (non-significant) binding was observed for K3 for PSMA-11 (see fig. 1), but also with faster K4, suggesting reversible kinetics. For PSMA-1007 K4 was very low for all lesion types, in-keeping with irreversible kinetics (see fig. 2). For all lesions, including UBU, no significant differences were seen for the specific distribution volume (Vs) suggesting that non-specific binding is not the cause of the higher frequency of UBU seen in PSMA-1007 or of ganglia in PSMA-11. For net influx Ki statistical significance was reached for nodal ganglia and borderline higher net influx for local recurrence (p=0.08) for PSMA-11.

Conclusions: Parametric analysis showed clear intravidual in vivo differences in tracer kinetics, with irreversible kinetics seen in [18F]PSMA-1007 and reversible kinetics for [68Ga]Ga-PSMA-11. A statistically higher net influx was seen for [68Ga]Ga-PSMA-11 in Ganglia. Otherwise, there were no clear differences were seen for both tracers with largely comparable kinetics in most normal organs and malignant lesions. Parametric imaging could not reveal differences between malignant lesions and non specific foci (e.g. UBU).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparative whole-body multi-parametric [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT: a randomised and prospective intra-individual comparison of tracer dynamics
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Comparative whole-body multi-parametric [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT: a randomised and prospective intra-individual comparison of tracer dynamics
Ian Alberts, Hasan Sari, Clemens Mingels, Axel Rominger, Ali Afshar-Oromieh
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 242480;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comparative whole-body multi-parametric [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT: a randomised and prospective intra-individual comparison of tracer dynamics
Ian Alberts, Hasan Sari, Clemens Mingels, Axel Rominger, Ali Afshar-Oromieh
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 242480;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Head-to-head Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT in Fumarate Hydratase-Deficient Renal Cell Carcinoma
  • Comparison of Post-Therapy 4 and 24-hour 177Lu-PSMA SPECT/CT and Pre-Therapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castrate-Resistant Prostate Cancer
  • Clinical relevance of post-therapy SPECT/CT in prostate cancer patients treated with Lutetium Lu 177 vipivotide tetraxetan
Show more Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - GU

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire